Tolvaptan, hyponatremia, and heart failure

Tolvaptan is the first FDA-approved oral V(2) receptor antagonist for the treatment of euvolemic and hypervolemic hyponatremia, in patients with conditions associated with free water excess such as heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion. Tolvaptan...

Descripción completa

Detalles Bibliográficos
Autores principales: Zmily, Hammam D, Daifallah, Suleiman, Ghali, Jalal K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108793/
https://www.ncbi.nlm.nih.gov/pubmed/21694950
http://dx.doi.org/10.2147/IJNRD.S7032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108793/
https://www.ncbi.nlm.nih.gov/pubmed/21694950
http://dx.doi.org/10.2147/IJNRD.S7032

Ejemplares similares